Policy Brief: An Evidence-Based Roadmap for the Equitable Elimination of HPV-Related Cancers by 2035

<ns3:p>Background The convergence of highly effective prophylactic HPV vaccination and sensitive HPV-based screening technologies presents a historic opportunity to eliminate cervical cancer and reduce other HPV-related malignancies. Despite the availability of these tools, systemic inequities in access and implementation remain the principal barrier to achieving global elimination targets. Objective This policy brief synthesizes the latest evidence to provide an evidence-based, context-sensitive roadmap for policymakers to overcome health systems, economic, and political barriers, guiding the equitable elimination of HPV-related cancers by 2035. Key Recommendations Robust evidence confirms the high efficacy of HPV vaccination, including the transformative potential of single-dose schedules for improving equity and scalability. Primary HPV screening, particularly when coupled with self-sampling, offers superior protection and increases uptake. Success hinges on addressing critical implementation challenges. The brief outlines a comprehensive framework emphasizing: the adoption of gender-neutral and single-dose vaccination; integration of self-sampling and digital health tools; proactive interventions for marginalized groups; development of national investment cases; and the use of multi-sectoral task forces and community engagement to mitigate socio-cultural barriers. A phased three-year operational roadmap is proposed. Conclusion The elimination of HPV-related cancers is an achievable goal. This brief provides a strategic, evidence-informed pathway for policymakers to translate scientific progress into lasting population health impact through deliberate political commitment, financial investment, and health system reforms focused on equity.</ns3:p>